中国药企发力研发创新药征募志愿者参加研究

2014-08-29 17:14:36来源：可可英语

　　One of those trying to make the leap from generic to innovative medicines is SimcerePharmaceuticals, which recently opened an R&D hub in Nanjing. Ren Jinsheng, thecompany’s founder and chairman, says funding remains a challenge. “Compared to the $30bninvested by the US government each year in fundamental drug research, the Chinesegovernment invests less than Rmb10bn [$1.6bn] and, at the company level, the gap is evenlarger.”

　　一些中国制药商正在尝试完成从仿制药到创新药的飞跃，先声药业(Simcere Pharmaceuticals)就是其中一家，它最近在南京成立了研发中心。先声药业创始人兼董事会主席任晋生表示，资金仍然是个难题。“相比美国政府每年300亿美元的基础药物研究投入，中国政府每年的投入还不到100亿元人民币(合16亿美元)，在企业层面上，两国的差距更大。”

　　There are signs, however, that the gap is beginning to narrow.

　　然而，有迹象显示，这种差异已开始缩小。

　　Between 2007 and 2012, Chinese investment in biomedical R&D grew at a compoundannual rate of 33 per cent, compared with an average 7 per cent in the rest of Asia-Pacific,according to McKinsey, the consultant. This increased spending is beginning to produceresults: the number of Chinese papers in respected life science journals rose more than sixfoldbetween 2001 and 2013, says Fangning Zhang of McKinsey in Shanghai.

　　咨询公司麦肯锡(McKinsey)的数据显示，2007年至2012年期间，中国的生物研发投资规模以每年33%的复合增长率增长，而亚太其他国家的平均增长率是7%。麦肯锡驻香港的张芳宁表示，增加投入已初见成效：中国人在权威生命科学期刊上发表的论文数量，在2001年至2013年之间增长了5倍。

　　Skills shortages are another obstacle being gradually overcome, as China’s universities churnout young scientists and those trained in the west return home.

　　技能短缺的障碍也逐渐被克服，中国的大学输送着一批接一批的年轻科学家，还有许多在西方接受了训练的中国科学家返回中国。

　　Even so, the regulatory environment remains difficult, according to Carl Firth, a formerAstraZeneca executive in China who is now chief executive of Aslan Pharmaceuticals, an Asia-focused drug developer. He says early-stage trials are easier to carry out elsewhere in Asia.

　　即便如此，曾任阿斯利康驻中国高管、现任聚焦亚洲的药物开发商Aslan Pharmaceuticals首席执行官的卡尔•弗思(Carl Firth)表示，监管环境仍然严峻。他说，在亚洲其他地方，开展早期试验的难度比中国更低。

　　“If there was a serious push by regulators to speed up the process, the biggest beneficiarieswould be multinationals because Chinese companies are not ready,” Mr Firth argues. “China isgoing to be a major player in pharma R&D, but they are not about to overtake the USand Europe. One day maybe, but not yet.”

　　“如果监管机构真正着手推动流程加速，那么最大的受益者将会是跨国制药商，因为中国制药商还没准备好。”弗思指出，“中国将成为医药研发中的重要力量，但中国还不至于很快超越美国和欧洲。未来或许可以，但现在还不行。”

本文关键字: 中国药企发力研发创新药